These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 22267719)

  • 1. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study.
    Walker WT; de Whalley P; Andrews N; Oeser C; Casey M; Michaelis L; Hoschler K; Harrill C; Moulsdale P; Thompson B; Jones C; Chalk J; Kerridge S; John TM; Okike I; Ladhani S; Tomlinson R; Heath PT; Miller E; Faust SN; Snape MD; Finn A; Pollard AJ
    Clin Infect Dis; 2012 Mar; 54(5):661-9. PubMed ID: 22267719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
    de Whalley P; Walker W; Snape MD; Oeser C; Casey M; Moulsdale P; Harrill C; Andrews N; Hoschler K; Thompson B; Jones C; Chalk J; Kerridge S; Tomlinson R; Heath PT; Finn A; Faust S; Miller E; Pollard AJ
    Health Technol Assess; 2011 Dec; 15(45):v-vi, xi-xiii, 1-128. PubMed ID: 22257497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
    Waddington CS; Walker WT; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston PE; Allen RJ; Okike I; Ladhani S; Sheasby E; Hoschler K; Andrews N; Waight P; Collinson AC; Heath PT; Finn A; Faust SN; Snape MD; Miller E; Pollard AJ
    BMJ; 2010 May; 340():c2649. PubMed ID: 20508026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
    Langley JM; Scheifele DW; Quach C; Vanderkooi OG; Ward B; McNeil S; Dobson S; Kellner JD; Kuhn S; Kollman T; MacKinnon-Cameron D; Smith B; Li Y; Halperin SA
    Vaccine; 2012 May; 30(23):3389-94. PubMed ID: 22469860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
    Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
    Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
    Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
    Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.
    Vesikari T; Richardus JH; Berglund J; Korhonen T; Flodmark CE; Lindstrand A; Silfverdal SA; Bambure V; Caplanusi A; Dieussaert I; Roy-Ghanta S; Vaughn DW
    Pediatr Infect Dis J; 2015 Jul; 34(7):774-82. PubMed ID: 26069949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.
    Andrews NJ; Walker WT; Finn A; Heath PT; Collinson AC; Pollard AJ; Snape MD; Faust SN; Waight PA; Hoschler K; Sheasby L; Waddington C; Kerridge S; Chalk J; Reiner A; John T; Fletcher M; Allen R; Fineman N; Wilkins S; Casey M; Michaelis L; Oeser C; Okike I; Ladhani S; Miller E
    Vaccine; 2011 Oct; 29(45):7913-9. PubMed ID: 21875635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
    Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
    Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
    Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
    Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart.
    Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina M; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
    Health Technol Assess; 2010 Dec; 14(55):193-334. PubMed ID: 21208550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
    Clark TW; Pareek M; Hoschler K; Dillon H; Nicholson KG; Groth N; Stephenson I
    N Engl J Med; 2009 Dec; 361(25):2424-35. PubMed ID: 19745215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
    Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
    Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.